Eagle Pharmaceuticals, Inc. (EGRX)

Eagle Pharmaceuticals, Inc. (EGRX) Healthcare & Pipeline Overview

Eagle Pharmaceuticals, Inc. develops and commercializes specialized product candidates across central nervous system, metabolic critical care, and oncology therapeutic areas in the U.S. The company leverages a portfolio of approved drugs like Ryanodex and Bendeka, alongside a pipeline of innovative therapies and strategic collaborations, positioning it within the specialty and generic drug manufacturing industry.

What Is the Investment Thesis for EGRX?

Eagle Pharmaceuticals, Inc. presents an investment thesis centered on its established portfolio of commercialized specialty drugs and a diversified pipeline addressing critical medical needs. The company's existing products, Ryanodex, Belrapzo, and Bendeka, provide a foundation of revenue, contributing to a robust gross margin of 70.0% and a profit margin of 11.3%. The low P/E ratio of 0.0 suggests potential undervaluation relative to current earnings, while a Beta of 0.60 indicates lower volatility compared to the broader market. Growth catalysts are primarily driven by the advancement of its late-stage product candidates, such as PEMFEXY for oncology and EP-4104 for organophosphate exposure, which target substantial market opportunities. Strategic license agreements for CAL02 and Landiolol, alongside the collaboration with Tyme Technologies for SM-88, further diversify potential revenue streams and reduce reliance on a single product. The company's focus on specialty and critical care markets, coupled with its ongoing development efforts and partnerships, positions it to capture value from new product launches and expanded indications, subject to regulatory approvals and market adoption.

Based on FMP financials and quantitative analysis

EGRX Key Highlights

• Gross Margin of 70.0% indicates strong profitability on its core product sales, exceeding many industry benchmarks for specialty pharmaceuticals.
• Profit Margin of 11.3% demonstrates the company's ability to convert revenues into net income, reflecting efficient operational management.
• A P/E ratio of 0.0 suggests that the company's stock may be trading at a low multiple relative to its earnings, potentially indicating undervaluation.
• Beta of 0.60 signifies lower volatility compared to the overall market, suggesting a more stable equity performance profile for investors.
• The company manages 134 employees, indicating a focused operational structure for a specialty pharmaceutical firm with both commercialized products and a development pipeline.

Who Are EGRX's Competitors?

EGRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EGRX's Key Strengths?

• Established portfolio of commercialized specialty drugs (Ryanodex, Belrapzo, Bendeka) providing current revenue streams.
• Diversified product pipeline targeting multiple therapeutic areas including oncology, critical care, and CNS.
• Strategic license and collaboration agreements (e.g., Combioxin, AOP Orphan, Tyme Technologies) expanding development capabilities and market reach.
• Strong gross margin of 70.0% indicating efficient production and pricing power for its specialty products.

What Are EGRX's Weaknesses?

• Reliance on a relatively small number of commercialized products for current revenue, making it susceptible to market shifts or competition for these drugs.
• Significant portion of future growth dependent on successful clinical development and regulatory approval of pipeline candidates, which is inherently risky.
• As an OTC-traded company, it may face challenges in attracting institutional investment and maintaining liquidity compared to exchange-listed peers.
• Disclosure status on OTC market is 'Unknown', potentially limiting investor confidence and transparency.

What Could Drive EGRX Stock Higher?

• Potential regulatory approvals for pipeline candidates such as PEMFEXY for non-small cell lung cancer and mesothelioma, or EA-114 (fulvestrant) for HR+/HER- breast cancer, which could significantly expand market opportunities.
• Advancement of EP-4104, a dantrolene sodium to treat organophosphate exposure, through clinical trials and towards regulatory submission, potentially addressing a critical unmet medical need.
• Progress in the development and commercialization efforts for licensed products like CAL02 (antitoxin for severe pneumonia) and Landiolol (for supraventricular tachycardia), which could open new therapeutic markets.
• Further developments and clinical data releases from the strategic collaboration with Tyme Technologies, Inc. for SM-88, targeting breast cancer and high-risk metastatic sarcomas.
• Introduction of new formulations or expanded indications for existing commercialized products (Ryanodex, Belrapzo, Bendeka) to extend their market lifecycle and reach.

What Are the Key Risks for EGRX?

• Financial-distress signal — its Altman Z-Score of 1.68 sits in the distress zone (elevated bankruptcy risk).
• Clinical trial failures or regulatory setbacks for its pipeline candidates, including EP-4104, PEMFEXY, EA-114, and Vasopressin injection, which could delay or prevent market entry.
• Intense competition in the specialty and generic drug manufacturing industry from larger pharmaceutical companies and emerging biotechs, potentially impacting market share and pricing power.
• Patent expirations or challenges to its intellectual property for commercialized drugs, leading to generic competition and erosion of revenue streams.
• Dependence on the success of strategic collaborations and license agreements, where the company's control over development and commercialization may be limited by partner decisions.
• As an OTC-traded stock with 'Unknown' disclosure status, Eagle Pharmaceuticals faces heightened risks related to liquidity, price volatility, and investor confidence due to limited public financial information.

What Are the Growth Opportunities for EGRX?

• Advancement and Commercialization of Oncology Pipeline Candidates: Eagle Pharmaceuticals has several promising oncology candidates, including PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma, and EA-114 (fulvestrant) for HR+/HER- breast cancer. Additionally, its collaboration with Tyme Technologies, Inc. for SM-88 targets breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. The global oncology drug market is projected to reach significant valuations, with specific segments like lung cancer and breast cancer therapies representing multi-billion dollar opportunities. Successful regulatory approval and market penetration of these candidates could substantially expand Eagle's revenue base within the next 3-5 years, leveraging its existing commercial infrastructure.
• Expansion into Critical Care and Central Nervous System Markets with Novel Therapies: The company's pipeline includes EP-4104, a dantrolene sodium formulation to treat organophosphate exposure, and Vasopressin injection for vasodilatory shock. These products address critical, often life-threatening conditions with significant unmet needs. The market for critical care drugs, particularly those addressing acute toxic exposures or hemodynamic instability, is robust. Successful development and launch of EP-4104 could tap into a specialized emergency medicine market, while Vasopressin injection could enhance its presence in hospital critical care settings. These opportunities could materialize within a 2-4 year timeframe, contingent on clinical trial success and regulatory clearances.
• Leveraging Strategic License and Collaboration Agreements for Market Diversification: Eagle Pharmaceuticals has secured license and collaboration agreements for product candidates like CAL02 with Combioxin, SA, an antitoxin agent for severe pneumonia, and Landiolol with AOP Orphan Pharmaceuticals GmbH, for supraventricular tachycardia. These agreements provide access to innovative therapies developed by partners, expanding Eagle's therapeutic reach without the full R&D burden. The global market for anti-infectives and cardiovascular drugs are substantial, with pneumonia and cardiac arrhythmias being prevalent conditions. Successful development and commercialization of CAL02 and Landiolol, expected within the next 3-6 years, could open new revenue streams and diversify the company's product portfolio, reducing reliance on its existing commercialized drugs.
• Maximizing the Lifecycle and Market Penetration of Approved Products: Eagle Pharmaceuticals currently commercializes Ryanodex for malignant hyperthermia and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. These products represent established revenue streams. Opportunities exist to expand their market penetration through targeted marketing, physician education, and potentially exploring new indications or formulations if scientifically viable. While these products are mature, ensuring their continued market share and optimizing their commercial lifecycle remains a key growth driver. This ongoing effort provides a stable revenue base that can fund pipeline development, contributing to sustained growth over the long term.
• Strategic Partnerships and Acquisitions to Enhance Product Portfolio: The pharmaceutical industry frequently sees growth through strategic partnerships, licensing deals, and targeted acquisitions that complement existing product portfolios or pipelines. Eagle Pharmaceuticals' existing collaborations demonstrate its capability in this area. Future growth could involve identifying and integrating additional assets, whether through in-licensing late-stage candidates or acquiring smaller companies with synergistic product lines or technological platforms. Such strategic moves could accelerate market entry into new therapeutic areas or strengthen its position in existing ones, potentially leading to significant growth within a 1-5 year horizon depending on the nature and scale of the transactions.

What Opportunities Does EGRX Have?

• Successful launch and market penetration of late-stage pipeline candidates like PEMFEXY, EA-114, EP-4104, and Vasopressin injection.
• Expansion of existing product indications or formulations to capture new patient populations or extend product lifecycles.
• Further strategic collaborations or acquisitions to augment its pipeline and diversify its therapeutic portfolio.
• Capitalizing on unmet medical needs in its focused therapeutic areas through innovative drug development.

What Threats Does EGRX Face?

• Intensified competition from other pharmaceutical companies developing similar or superior therapies.
• Regulatory hurdles, delays, or outright rejections for its pipeline candidates, impacting future revenue potential.
• Patent expirations or loss of market exclusivity for its commercialized drugs, leading to generic competition and price erosion.
• Changes in healthcare policy, reimbursement landscapes, or economic conditions that could impact drug pricing and market access.

What Are EGRX's Competitive Advantages?

• Proprietary formulations and drug delivery technologies for its approved products and pipeline candidates, such as the ready-to-use/dilute liquid form of pemetrexed (PEMFEXY).
• Regulatory approvals and market exclusivity for its commercialized drugs like Ryanodex, Belrapzo, and Bendeka, providing a period of protection from generic competition.
• Strategic license and collaboration agreements that provide access to novel therapeutic assets and expand its pipeline without full internal R&D costs.
• Specialization in niche therapeutic areas (e.g., malignant hyperthermia, organophosphate exposure) where competition may be less intense compared to broader markets.

What Does EGRX Do?

Eagle Pharmaceuticals, Inc., incorporated in 2007 and headquartered in Woodcliff Lake, New Jersey, is a pharmaceutical company dedicated to the development and commercialization of product candidates within the United States. The company strategically focuses on therapeutic areas including diseases of the central nervous system, metabolic critical care, and oncology, addressing significant unmet medical needs. Eagle Pharmaceuticals has established a portfolio of commercialized products, notably Ryanodex, indicated for the treatment of malignant hyperthermia, a rare and life-threatening condition. Additionally, the company offers Belrapzo and Bendeka, both utilized in the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma, representing key revenue streams within its oncology segment. Beyond its marketed products, Eagle Pharmaceuticals maintains an active and diversified product pipeline. This includes EP-4104, a dantrolene sodium formulation under development for organophosphate exposure, and PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed targeting non-small cell lung cancer and mesothelioma. The pipeline also features EA-114 (fulvestrant) for HR+/HER- breast cancer and Vasopressin injection, designed to enhance blood pressure in adults experiencing vasodilatory shock. To further expand its therapeutic reach and product offerings, Eagle Pharmaceuticals engages in strategic license and collaboration agreements. A notable collaboration is with Combioxin, SA, granting Eagle development and commercialization rights for CAL02, an antitoxin agent intended for severe pneumonia treatment in conjunction with traditional antibacterial drugs. Another significant partnership is with AOP Orphan Pharmaceuticals GmbH, securing commercial rights for Landiolol, a novel therapeutic candidate aimed at the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. The company also maintains a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88, a promising compound for treating breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. These collaborations underscore Eagle Pharmaceuticals' strategy to leverage external innovation and expertise to broaden its market presence and address a wider spectrum of medical conditions.

What Products and Services Does EGRX Offer?

• Develops and commercializes pharmaceutical products for diseases of the central nervous system, metabolic critical care, and oncology.
• Offers Ryanodex, an approved drug for treating malignant hyperthermia.
• Markets Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.
• Advances EP-4104, a dantrolene sodium formulation for organophosphate exposure, through its pipeline.
• Develops PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma.
• Works on EA-114 (fulvestrant) for HR+/HER- breast cancer and Vasopressin injection for vasodilatory shock.
• Collaborates with Combioxin, SA for CAL02, an antitoxin agent for severe pneumonia.
• Partners with AOP Orphan Pharmaceuticals GmbH for Landiolol, a product candidate for supraventricular tachycardia.

How Does EGRX Make Money?

• Generates revenue from the sales of its commercialized proprietary drugs, including Ryanodex, Belrapzo, and Bendeka, to healthcare providers and institutions.
• Seeks to monetize its product pipeline through successful clinical development, regulatory approval, and subsequent commercial launch of new therapies.
• Engages in license and collaboration agreements, potentially involving upfront payments, milestone payments, and royalties on future sales of partnered products.
• Focuses on specialty pharmaceutical markets, often characterized by higher margins and targeted sales efforts to specific medical specialists.

What Industry Does EGRX Operate In?

Eagle Pharmaceuticals, Inc. operates within the highly specialized and competitive Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector. This industry is characterized by significant R&D investment, stringent regulatory pathways, and a constant need for innovation to address evolving medical challenges. Market trends include a growing demand for targeted therapies, an increasing focus on orphan drugs for rare diseases, and the ongoing development of biosimilars and generic alternatives to established branded drugs. Eagle Pharmaceuticals positions itself by focusing on niche markets within central nervous system, metabolic critical care, and oncology, where its approved products like Ryanodex and Bendeka serve specific patient populations. The competitive landscape includes large pharmaceutical companies with extensive resources, as well as smaller, agile biotech firms. Eagle's strategy of both developing proprietary products and leveraging license and collaboration agreements allows it to compete by expanding its pipeline and market reach without solely relying on internal R&D, navigating the complexities of drug development and commercialization.

Who Are EGRX's Key Customers?

• Hospitals and medical centers that utilize critical care drugs like Ryanodex and Vasopressin injection.
• Oncology clinics and specialists prescribing treatments for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and breast cancer.
• Emergency medical services and public health agencies for potential use of products like EP-4104 for organophosphate exposure.
• Specialty pharmacies and distributors that facilitate the supply chain for its pharmaceutical products.

Company Profile

Eagle Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Woodcliff Lake, US. The company is led by CEO Michael Graves. EGRX has traded publicly since 2014.

Eagle Pharmaceuticals, Inc. (EGRX) Valuation Context

Valued at $8.82M, EGRX is classified as a micro-cap stock. Relative to its peer group, EGRX's quantitative score of 60/100 is roughly in line with the peer average of 66/100.

ROE 17%Key Financial Metrics

Return on equity for Eagle Pharmaceuticals, Inc. stands at 17.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.8%, showing how much profit it generates from its asset base. EGRX trades at a trailing price-to-earnings ratio of 0.03, below the Healthcare sector average of ~23x. A current ratio of 1.70 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 4/9Financial Health

Eagle Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.68 places it in the distress zone, a signal of elevated financial risk.

EGRX Financials

EGRX Latest News

EGRX Analyst Consensus

EGRX MoonshotScore

EGRX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources